clinical trials glp-1 Another milestone in the evolution of GLP-1-based diabetes therapies Real-World Evidence for GLP-1 Receptor – How Can GLP-1 Agonists Be

10.1016/j.abb.2018.11.005 42 IannuzzoF.SchianoE.PastoreA.GuerraF.TenoreG

This is especially true if you get it from foods rather than from supplements

For KPV, TB-500 and MOTS-c, FDA reported no human clinical evidence at all

Other sources of omega-3 fatty acids include fatty fish like sardines, mackerel and herring

Research has linked synephrine to potential adverse cardiovascular effects, including elevated heart rate and blood pressure

Considering the significantly elevated expression levels of GLP-1R in diabetic patients, it is hypothesized that administration of GLP-1R agonists may elevate the risk of breast cancer progression in these patients, thus necessitating particular caution in clinical management [101]